Clark Estates Inc. NY Sells 13,112 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Key Points

• Clark Estates Inc. NY reduced its stake in Bristol Myers Squibb by 27.5% during the first quarter, bringing its total holdings to 34,538 shares.
• Multiple institutional investors have adjusted their positions, with Global Wealth Strategies & Associates increasing their stake by 137.5% in the first quarter.
• Wall Street analysts have issued mixed ratings on Bristol Myers Squibb, with a consensus rating of "Hold" and an average price target of $58.53.

Clark Estates Inc. NY cut its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 27.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 34,538 shares of the biopharmaceutical company's stock after selling 13,112 shares during the period. Clark Estates Inc. NY's holdings in Bristol Myers Squibb were worth $2,106,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Ameriprise Financial Inc. lifted its holdings in Bristol Myers Squibb by 59.9% in the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock worth $1,814,341,000 after acquiring an additional 12,011,983 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in Bristol Myers Squibb by 701.2% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock worth $705,309,000 after acquiring an additional 10,913,708 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Bristol Myers Squibb by 3,880.0% in the fourth quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock worth $338,088,000 after acquiring an additional 5,827,317 shares during the last quarter. Northern Trust Corp lifted its holdings in Bristol Myers Squibb by 16.2% in the fourth quarter. Northern Trust Corp now owns 24,658,360 shares of the biopharmaceutical company's stock worth $1,394,677,000 after acquiring an additional 3,431,248 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in Bristol Myers Squibb by 72.9% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 7,769,227 shares of the biopharmaceutical company's stock worth $439,427,000 after acquiring an additional 3,275,061 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Citigroup cut their target price on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a report on Friday. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 price target on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Argus raised Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Finally, Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $57.33.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock traded up $0.94 on Friday, reaching $44.25. 18,626,740 shares of the stock were exchanged, compared to its average volume of 12,693,902. The stock has a market cap of $90.05 billion, a PE ratio of 17.84, a PEG ratio of 2.35 and a beta of 0.36. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. Bristol Myers Squibb Company has a twelve month low of $42.96 and a twelve month high of $63.33. The firm has a fifty day moving average price of $47.51 and a two-hundred day moving average price of $52.26.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. The firm had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.60%. The business's revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.07 EPS. Sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were given a dividend of $0.62 per share. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.6%. Bristol Myers Squibb's dividend payout ratio is currently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.